Results 11 to 20 of about 120,218 (287)

Cytotoxic T lymphocyte antigen-4 (CTLA-4) A49G polymorphism and autoimmune blood diseases [PDF]

, 2010
Objective: The cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is expressed on T lymphocytes, and inhibits the T-cell responses. In animal models, it has been shown that complete CTLA-4 deficiency was lethal due to massive infiltration of tissues by
Faruk Aktürk, Reyhan Küçükkaya, Veysel Sabri Hançer   +2 more
core   +1 more source

CTLA-4 trafficking and surface expression [PDF]

Trends in Immunology, 2008
The T-cell co-receptor cytotoxic T-cell antigen 4 (CTLA-4) has a strong inhibitory role as shown by the lymphoproliferative phenotype of CTLA-4-deficient mice. Despite its potent effects on T-cell function, CTLA-4 is primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid ...
Elke, Valk, Christopher E, Rudd, Helga, Schneider   +2 more
openaire   +2 more sources

Polymorphism analysis of the CTLA-4 gene in paracoccidioidomycosis patients [PDF]

, 2011
The CTLA-4 protein is expressed in activated T cells and plays an essential role in the immune response through its regulatory effect on T cell activation.
Alfredo M Goes, Anamelia L Bocca, Balbi G, Barreto M, Barrett JC, Blomhoff A, Bocca AL, Bozzi A, Bozzi A, Butty V, Campanelli AP, Carvalho A, Cavassani KA, Dariavach P, Deichmann K, Franco M, Ghaderi A, Goldstein DB, Gough SC, Guzman VB, Han S, Harper K, Holopainen P, Izabel Cristina R Silva, Kouki T, Kristiansen OP, Lee YH, Ligers A, Ling V, Lins TC, Lins TC, Lins TC, Marcus M Teixeira, Maria Heloisa SL Blotta, Maria Sueli S Felipe, Martins GA, Moreno Lima R, Nisticò L, Pritchard JK, Restrepo A, Rinaldo W Pereira, Rodrigo G Vieira, Rosenberg NA, Silva CL, Smith MW, Su TH, Thio CL, Tomer Y, Tulio C Lins, Ueda H, van Belzen MJ, Viviane F Lozano, Wang XB, Yanagawa T, Zaletel K   +54 more
core   +4 more sources

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity

Cancer Science, 2023
AbstractCombination therapy with anti‐cytotoxic T lymphocyte‐associated protein 4 (CTLA‐4) and anti‐programmed death‐1 (PD‐1) monoclonal antibodies (mAbs) has dramatically improved the prognosis of patients with multiple types of cancer, including renal cell carcinoma (RCC).
Tomofumi Watanabe, Takamasa Ishino, Youki Ueda, Joji Nagasaki, Takuya Sadahira, Hiromichi Dansako, Motoo Araki, Yosuke Togashi   +7 more
openaire   +3 more sources

CTLA-4 and PD-1 ligand gene expression in epithelial thyroid cancers [PDF]

, 2018
The dysregulation of PD-1 ligands (PD-L1 and PD-L2) and CTLA-4 ligands (CD80 and CD86) represents a tumor strategy to escape the immune surveillance. Here, the expression of PD-L1, PD-L2, CD80 and CD86 was evaluated at mRNA level in 94 patients affected ...
Antonelli, Alessandro, Arcieri, Stefano, Baldini, Enke, Barollo, Susi, Carbotta, Giovanni, Catania, Antonio, Fallahi, Poupak, Mian, Caterina, Monti, Massimo, Palmieri, Andrea, Pironi, Daniele, Sorrenti, Salvatore, Tartaglia, Francesco, Tuccilli, Chiara, Ulisse, Salvatore, Vergine, Massimo   +15 more
core   +3 more sources

Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis [PDF]

, 2009
Targeted immune-modulating agents are entering clinical practice in many specialties, providing novel therapeutic possibilities but introducing new potential toxicities.
Clatworthy, Menna R, Farrington, Ken, Jolly, Elaine C, Lawrence, Christopher, Nathan, Paul D   +4 more
core   +2 more sources

Potent Inhibition of CTLA-4 Expression by an Anti-CTLA-4 Ribozyme

Biochemical and Biophysical Research Communications, 1998
Blockading the negative-regulatory CTLA-4 receptor has emerged as a powerful strategy with clinical potential to enhance T-cell responses. Some experimental tumors, for example, are rejected when anti-CTLA-4 antibodies are administered in vivo. The concise target cells and downstream events, however, remain to be defined.
E, Cepero, H J, Hnatyszyn, G, Kraus, M G, Lichtenheld   +3 more
openaire   +2 more sources

The gut microbiota and immune checkpoint inhibitors. [PDF]

, 2018
Although immunotherapy has been remarkably effective across multiple cancer types, there continues to be a significant number of non-responding patients. A possible factor proposed to influence the efficacy of immunotherapies is the gut microbiome.
Daud, Adil, Humphries, Audrey
core   +1 more source

Immune checkpoint inhibitors in renal cell carcinoma [PDF]

, 2017
The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for therapeutic gain.
Jones, Robert J., Ross, Kirsty
core   +1 more source

Augmentation of CTLA-4 expression by wortmannin: involvement of lysosomal sorting properties of CTLA-4 [PDF]

International Immunology, 1999
CTLA-4 (CD152) is transiently induced on the cell surface of activated T cells and expression is limited at a low level. In this study, we investigated the possibility that phosphatidylinositol 3 kinase (PI 3-K) and other related PI kinases associated with the cytoplasmic domain of CTLA-4 are involved in intracellular trafficking and sorting of CTLA-4 ...
S, Oki, T, Kohsaka, M, Azuma
openaire   +2 more sources